FRIDAY, JUNE 22, 2018

Celerion expands Belfast facility

Celerion announced on June 5 the addition of a containment room to its Belfast, Northern Ireland U.K. facility.

The new containment room will give Celerion the opportunity to develop programs that require studies utilizing biologics. It will also allow Celerion to study vaccines that have primary and secondary containment.

The containment room is a modular facility made up of a negative pressure processing room that also houses a biosafety level cabinet. This newest addition to the Celerion Belfast facility helps to further enhance the GMP licensed site by enabling the processing of live class 2 and class 3 biological products.

"The addition of the containment room, coupled with our ability in the Belfast clinic to recruit large numbers of study participants, places Celerion in a strong position to conduct studies requiring biologics and vaccines," Phil Bach, vice president of Global Clinical Research at Celerion, said. "Celerion's facility in Belfast continues to go from strength to strength. This announcement builds on the recent addition of the Bronchoscopy Suiteand expansion of our services in the respiratory therapeutic area. The Belfast clinic is widely recognized as the Respiratory Centre of Excellence with experience in asthma, COPD, cystic fibrosis, and bronchiectasis clinical research."

In addition to the containment room, the facilities in Belfast also have early stage clinical capabilities based on First-In-Human experience with both NCEs and biologics.